27 March 2018
: Case report
Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer
Adverse events of drug therapy
Tomokazu Iyoda1ABCDEF, Noriaki Kurita23ADEF*, Ayumi Takada1BC, Hiroe Watanabe1BC, Masahiro Ando4BCDFDOI: 10.12659/AJCR.908570
Am J Case Rep 2018; 19:360-364
Abstract
BACKGROUND: Enterocolitis is an immune-related adverse event associated with nivolumab treatment. Although intravenous corticosteroids and infliximab are recommended as a first-line and second-line therapy, respectively, there is no established treatment for severe enterocolitis that is refractory to these drugs.
CASE REPORT: A 62-year-old male with non-small cell lung cancer, with multiple brain metastasis, received nivolumab as the eighth-line chemotherapy for his disease. A few days after nivolumab administration, grade 2–3 enterocolitis developed in the patient. The enterocolitis improved to grade 1 after careful observation; however, it was aggravated to grade 3 after resuming nivolumab treatment. After cessation of nivolumab, 3.3 mg of intravenous dexamethasone and 40 mg of methylprednisolone were administered for 16 days and subsequently 30–60 mg of oral prednisolone was administered for 50 days, with little improvement in the patient’s colitis. A second-line treatment with 5 mg/kg of infliximab was twice attempted, but the patient had persistent diarrhea. Therefore, 50 mg of oral cyclosporine was started as a third-line therapy. Three days after the start of cyclosporine, the number of diarrhea events decreased, with resolution 2 weeks after cyclosporine administration.
CONCLUSIONS: Oral cyclosporine treatment can be a third-line therapy for enterocolitis associated with immune-related adverse events.
Keywords: Cyclosporine, Drug-Related Side Effects and Adverse Reactions, Enterocolitis
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947160
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947567
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948238
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947782
Most Viewed Current Articles
21 Jun 2024 : Case report
100,489
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
53,790
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
36,376
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,034
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200